Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 16,553 matching trials from the live ClinicalTrials.gov search.
Conditions
Atopic Dermatitis (Eczema)
Interventions
ARQ-151 cream 0.15%, ARQ-151 cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Rancho Santa Margarita, California • Coral Gables, Florida + 7 more
Conditions
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes
Interventions
Clinical Trial Matching
Other
Lead sponsor
Massive Bio, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2040
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Steroid-reducing Effects of Crisaborole

NCT03832010
Conditions
Atopic Dermatitis, Eczema
Interventions
Crisaborole, Hydrocortisone Ointment, Triamcinolone ointment, Aquaphor
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
2 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Oily Skin, Seborrhea
Interventions
MTC896 Gel
Drug
Lead sponsor
Mimetica Pty Limited
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Paramus, New Jersey
Conditions
Actinic Keratoses
Interventions
Imiquimod
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Conditions
Cancer
Interventions
eFT508
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
Conditions
Gynecologic Cancers, Breast Cancer
Interventions
Mindful After Cancer Program
Behavioral
Lead sponsor
Oregon State University
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Corvallis, Oregon • Philadelphia, Pennsylvania
Conditions
Systemic Sclerosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Los Angeles, California • Boca Raton, Florida • Boston, Massachusetts + 3 more
Completed Phase 2 Interventional Results available

A Study of Deucravacitinib to Treat LPP and FFA

NCT06091956
Conditions
Lichen Planopilaris
Interventions
Deucravacitinib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Conditions
Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
Completed Not applicable Interventional Accepts healthy volunteers

Neurophysiological Evaluation of Training Effect on Cancer-Related Weakness

NCT02844504
Conditions
Breast Cancer
Interventions
Low Intensity Exercise Training 1, Low Intensity Exercise Training 2
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
West Orange, New Jersey
Conditions
Port Wine Stain
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Prurigo
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 15 more
Terminated Phase 2 Interventional Results available

Multi-catheter High Dose Rate (HDR) Breast Brachytherapy

NCT00214149
Conditions
Breast Cancer
Interventions
brachytherapy
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Interventions
ER004
Biological
Lead sponsor
EspeRare Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Conditions
Tennis Elbow, Lateral Epicondylitis \(Tennis Elbow\), Lateral Elbow Tendinopathy
Interventions
CTM, Celestone
Device · Drug
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more
Conditions
Hidradenitis Suppurativa
Interventions
Brensocatib, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Phoenix, Arizona • Sacramento, California • Coral Gables, Florida + 22 more
Conditions
Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma
Interventions
PD-0332991
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Acne Vulgaris
Interventions
50 mg P005672-HCl, Placebo, 100 mg P005672-HCl
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years to 45 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 34 more
Conditions
Arthritis, Rheumatoid
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
7,308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 24 more
Conditions
Psoriasis
Interventions
ABBV-553, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
4
States / cities
Anaheim, California • Toluca, California • Port Orange, Florida + 1 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Access to Genetic Testing in Underserved Patients With Cancer

NCT06422455
Conditions
Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Ovarian Carcinoma, Pancreatic Exocrine Neoplasm, Stage IVB Prostate Cancer American Joint Committee on Cancer v8, Triple-Negative Breast Carcinoma
Interventions
Best Practice, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Interview, Survey Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Rochester, New York